STOCK TITAN

ImmunityBio, Inc. - IBRX STOCK NEWS

Welcome to our dedicated page for ImmunityBio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on ImmunityBio stock.

ImmunityBio, Inc. (symbol: IBRX) is a pioneering biotechnology company specializing in immuno-oncology and infectious disease treatments. With a focus on activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems, ImmunityBio is at the forefront of developing innovative molecular and product platforms.

The company's key platforms include the development of antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies. ImmunityBio is working on several significant product candidates, such as n-803, aldoxorubicin, and a second-generation adenovirus vector. These platforms are designed to activate natural killer (NK) cells, T cells, tumoricidal macrophages, and memory T cells, providing a comprehensive approach to cancer treatment and infectious disease management.

Anktiva, one of ImmunityBio's leading product candidates, is an IL-15 superagonist antibody-cytokine fusion protein, which enhances the body's immune response against cancer cells. The company's pipeline includes treatments targeting bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).

Headquartered in the United States, ImmunityBio operates across two geographical segments: the United States and Europe, with key revenue generated from European markets. The company is integrated from discovery and development to commercialization, ensuring a seamless transition of its products from the laboratory to the market.

ImmunityBio has achieved several milestones, including the initiation of pivotal clinical trials and strategic partnerships with leading research institutions. These accomplishments underscore the company's commitment to transforming the landscape of immuno-oncology and infectious disease treatment.

Stay informed about ImmunityBio's latest developments, financial performance, and upcoming projects by visiting our news section regularly.

Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Patrick Soon-Shiong will present at the 2021 Jefferies London Healthcare Conference from November 16-18, 2021. His presentation on November 18 will focus on advancements in the company’s infectious disease and oncology programs. Attendees can access the on-demand webcast starting at 8:00 am GMT. ImmunityBio is advancing over 40 clinical trials, including their lead product Anktiva™ for bladder cancer, which has received FDA's Breakthrough Therapy designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
conferences
-
Rhea-AI Summary

ImmunityBio announced positive results from its Phase 2/3 trial of Anktiva (N-803) combined with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer. Both cohorts met primary endpoints: 57% disease-free survival after 12 months in cohort B (papillary disease) and a 72% complete response rate in cohort A (carcinoma in situ). Importantly, the therapy had no severe adverse events. A key patent for Anktiva use in bladder cancer has been granted, extending coverage until 2035.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
-
Rhea-AI Summary

CytRx Corporation highlights the early efficacy of its licensed drug aldoxorubicin in ImmunityBio's Phase 2 trial for advanced pancreatic cancer. The trial shows that 90% of evaluable patients exceeded historical survival rates, with 87% of those with extremely advanced disease also surpassing these rates. Mature data is expected in Q1 2022, and ImmunityBio is expanding enrollment due to positive early results. CytRx has potential milestone payments of up to $343 million from ImmunityBio for aldoxorubicin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
Rhea-AI Summary

ImmunityBio has completed enrollment of 50 participants in Cohort C of its QUILT 88 trial, focusing on advanced metastatic pancreatic cancer. The early results show that 90% of evaluable patients surpassed the two-month historical survival rate with standard chemotherapy. Among the most advanced patients, 87% exceeded these rates. The company plans to increase enrollment due to the positive early data and aims to discuss approval pathways with the FDA in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Summary

ImmunityBio, a clinical-stage immunotherapy company, has announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial, to evaluate its IL-15 receptor superagonist complex, N-803 (Anktiva), combined with Merck's pembrolizumab (Keytruda) for patients with non-small cell lung cancer (NSCLC) who have failed previous treatments. The study will target 478 patients and will be conducted at over 700 sites in the U.S. This landmark study aims to enhance treatment options for NSCLC patients without targetable mutations, providing a potential chemotherapy-free alternative with fewer side effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
-
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) reported promising results from its ongoing QUILT 3.032 bladder cancer trial, revealing that 72% of 81 patients achieved a complete response to the combination of intravesical BCG and N-803 (Anktiva). The median duration of this response was 19.9 months, with 85% of patients avoiding cystectomy as of May 2021. Moreover, there were no reported treatment-related serious adverse events. The data was presented on September 10 at the American Urological Association’s Annual Meeting, highlighting the drug's potential to redefine treatment for BCG-unresponsive patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) has appointed Helen Luu as its first Chief Commercial Officer and Sigrid Schreiner as Senior Vice President of Global Market Access. Luu, previously CEO of Cell BT, brings extensive experience in urology and oncology commercialization, while Schreiner has over 25 years in market access. These appointments are strategically aimed at enhancing ImmunityBio's commercialization efforts as it advances its Phase 2 and 3 clinical trials in bladder and lung cancer. The company aims to leverage their expertise to drive growth and market penetration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
management
-
Rhea-AI Summary

ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Karim Chamie from UCLA will present Phase 2/3 clinical results of IL-15 Superagonist N-803 combined with BCG for BCG-unresponsive bladder cancer at the American Urological Association's Annual Meeting on Sept. 10. Cohort A of the QUILT 3.032 trial now includes 81 subjects with a median follow-up exceeding 20 months. The trial has received Fast Track and Breakthrough Therapy Designations from the FDA, indicating significant potential for treating non-muscle invasive bladder cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
conferences clinical trial
-
Rhea-AI Summary

CytRx Corporation highlights the positive results from the Phase 2/3 trial of arimoclomol, an investigational treatment for Niemann-Pick disease type C. The study showed a significant treatment effect with a 65% relative reduction in disease progression over 12 months. Notably, in patients aged 4 and above, arimoclomol demonstrated an 82% reduction. The treatment was well-tolerated, with fewer serious adverse events compared to placebo. Orphazyme is awaiting a regulatory decision in Europe by Q4 2021 and is assessing the path forward in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
Rhea-AI Summary

ImmunityBio has been granted a patent (U.S. Patent 11,071,774) for its NANT Cancer Vaccine, enhancing its proprietary immunotherapy approach. This candidate aims to stimulate the immune system against cancers using natural killer and T-cell therapies and has been in clinical testing since 2017. The NANT Cancer Vaccine has been studied in over 100 patients across various cancers, with a Phase 2 trial (QUILT 88) focused on metastatic pancreatic cancer. The patent recognition reaffirms the innovative treatment strategy aimed at reducing chemotherapy toxicity while providing long-term immunity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags

FAQ

What is the current stock price of ImmunityBio (IBRX)?

The current stock price of ImmunityBio (IBRX) is $5.035 as of November 21, 2024.

What is the market cap of ImmunityBio (IBRX)?

The market cap of ImmunityBio (IBRX) is approximately 3.5B.

What does ImmunityBio, Inc. specialize in?

ImmunityBio specializes in immuno-oncology and infectious disease treatments, focusing on activating both the innate and adaptive immune systems.

What are the key product candidates of ImmunityBio?

Key product candidates include n-803, aldoxorubicin, and Anktiva, an IL-15 superagonist antibody-cytokine fusion protein.

Which cancers does ImmunityBio focus on treating?

ImmunityBio focuses on treating bladder, lung, and colorectal cancers, as well as glioblastoma multiforme (GBM).

What geographical segments does ImmunityBio operate in?

ImmunityBio operates in two geographical segments: the United States and Europe, with key revenue generated from Europe.

What types of therapies is ImmunityBio developing?

ImmunityBio is developing antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, as well as cell therapies.

How does ImmunityBio's Anktiva work?

Anktiva is an IL-15 superagonist antibody-cytokine fusion protein that enhances the body's immune response against cancer cells.

What recent achievements has ImmunityBio made?

ImmunityBio has initiated pivotal clinical trials and formed strategic partnerships with leading research institutions.

Where can I find the latest news about ImmunityBio?

You can stay informed about ImmunityBio's latest developments by visiting the news section on our website.

What is ImmunityBio's business model?

ImmunityBio is an integrated biotechnology company involved in discovering, developing, and commercializing immuno- and cellular therapies.

How does ImmunityBio contribute to cancer treatment?

ImmunityBio develops therapies that activate NK cells, T cells, tumoricidal macrophages, and memory T cells to enhance the immune system's ability to fight cancer.

ImmunityBio, Inc.

Nasdaq:IBRX

IBRX Rankings

IBRX Stock Data

3.49B
159.81M
77%
10.11%
7.57%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO